
MSD announced that its Phase 3 study of Keytruda (pembrolizumab) for the treatment of adults with relapsed or refractory classical …

Janssen has received final European sign-off for its oncology treatment Imbruvica (ibrutinib) as a treatment option for adult patients with …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

